Skip to Content

TG Therapeutics Inc TGTX

Morningstar Rating
$14.00 −0.07 (0.50%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

TGTX is trading within a range we consider fairly valued.
Price
$13.96
Fair Value
$77.58
Uncertainty
Very High
1-Star Price
$11.68
5-Star Price
$9.93
Economic Moat
Vbwkp
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if TGTX is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$14.07
Day Range
$13.7614.17
52-Week Range
$6.4635.67
Bid/Ask
$13.89 / $14.19
Market Cap
$2.16 Bil
Volume/Avg
100 / 3.6 Mil

Key Statistics

Price/Earnings (Normalized)
18.57
Price/Sales
9.35
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Growth
Total Number of Employees
264

Comparables

Valuation

Metric
TGTX
CELC
VRDN
Price/Earnings (Normalized)
18.57
Price/Book Value
13.883.143.46
Price/Sales
9.352,150.80
Price/Cash Flow
41.03
Price/Earnings
TGTX
CELC
VRDN

Financial Strength

Metric
TGTX
CELC
VRDN
Quick Ratio
5.0012.7817.93
Current Ratio
5.9213.4318.26
Interest Coverage
2.04−12.43−137.76
Quick Ratio
TGTX
CELC
VRDN

Profitability

Metric
TGTX
CELC
VRDN
Return on Assets (Normalized)
19.44%−35.57%−42.76%
Return on Equity (Normalized)
54.76%−49.08%−82.42%
Return on Invested Capital (Normalized)
35.76%−39.21%−50.70%
Return on Assets
TGTX
CELC
VRDN
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRLstfclchqRbw$551.2 Bil
VRTX
Vertex Pharmaceuticals IncVxgjhgjjhBnjgfw$101.9 Bil
REGN
Regeneron Pharmaceuticals IncPxvslzzkbNsqwzny$98.1 Bil
MRNA
Moderna IncVrjjdbtbHdv$39.7 Bil
ARGX
argenx SE ADRDjtlqwtdLyyn$22.1 Bil
BNTX
BioNTech SE ADRPlqjmrtkMlqnk$20.8 Bil
ALNY
Alnylam Pharmaceuticals IncRsvwcrsbwSycrqr$18.6 Bil
BMRN
Biomarin Pharmaceutical IncFgdvsqsWlpbbg$17.2 Bil
RPRX
Royalty Pharma PLC Class AQxznjlsgzLbvhw$12.3 Bil
INCY
Incyte CorpNpcjqdhrRlsltcq$11.9 Bil

Sponsor Center